Recombinant human interferon α2b biosimilar (Zhejiang Hansheng)

重组人干扰素α2b生物类似药（浙江北生）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interferon α2b biosimilar (Zhejiang Hansheng)
Drug Alias NameRecombinant human interferon A2b biosimilarrecombinant human interferon alfa-2b follow-on biologic莱福隆
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon-alpha/beta receptor alpha chain stimulants
TargetsInterferon-alpha/beta receptor alpha chain
Therapy Area/IndicationsNeoplasmsVirus Diseases
Global Approved IndicationsNeoplasmsVirus Diseases
Approved Indications in ChinaNeoplasmsVirus Diseases
Original Approved Country/TerritoryMainland China
Original Approved Date1999/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhejiang Hansheng Pharmaceutical Co Ltd Of Beisheng Pharma
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Hansheng Pharmaceutical Co Ltd Of Beisheng Pharma
Inactive CompaniesN/A
Active IndicationsNeoplasmsVirus Diseases
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A